Aetion and Cegedim Health Data Announce Long-Term Partnership to
Expand Real-World Evidence Research in Europe
Collaboration will power an RWE solution to assess the
utilization, safety, and effectiveness of treatments in near
real-time, across Europe
July 12, 2021 - Today, Aetion
and Cegedim Health
Data announced an expanded, 3-year partnership
that facilitates access to Cegedim
Health Data’s anonymized real-world data
through the Aetion Evidence
Platform® (AEP). Cegedim Health
Data’s The Health Improvement Network®
(THIN®) database
currently covers the United Kingdom, France, Spain, Italy, Belgium,
and Romania, with plans to add data from Germany. Following their
first year of partnership, Aetion
and Cegedim Health
Data have committed to further
collaboration, enabling customers
to monitor the utilization, safety, and effectiveness of medical
products at scale across Europe. Building on their
collaboration announced in 2020, the offering employs leading
trans-Atlantic real-world data to power regulatory-grade analytics
for biopharma companies, regulatory agencies, health
technology assessment (HTA) bodies, and public payers.
With THIN® data — which covers
large populations of over 69 million patients within
Europe —
loaded into the AEP, customers can
analyze the utilization, safety, and
effectiveness of treatments in near real time, which is especially
important for reviewing COVID-19 vaccines and
therapeutics.
“The
Aetion-Cegedim Health
Data partnership advances access to pan-European data
sources for real-world evidence research, and enables us to help
our customers navigate data privacy regulations and the
heterogeneity of data across countries,” said Carolyn Magill, CEO
of Aetion. “Combining Cegedim
Health Data’s THIN® database with the AEP is
critical as manufacturers, regulators, and HTAs work to assess the
utilization, safety, and effectiveness of interventions, as well as
the long-term impact of COVID-19.”
Gilles Paubert, Global
Head of Cegedim Health Data,
comments: “The COVID-19 pandemic has highlighted the relevance of
real-world patient data and has changed health sector attitudes on
the importance of recent, regularly updated data to help monitor
patient symptom trends, as well as the safety and efficacy of new
treatments for the benefit of public health. Paired with
Aetion’s platform, our clinically rich data
captured through THIN® will help deliver efficacious treatments to
patients more rapidly as we continue to battle COVID-19, and as we
look to the broader future for drug development.”
Aetion is a European Network of
Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP)
designated research center, and contributes to the ENCePP Working
Group 3, whose focus is to inventory EU data sources and define
methodological approaches for multi-source studies. In addition,
Aetion is engaged in a research collaboration with
the U.S. FDA to advance the agency’s understanding of and response
to COVID-19.
Global regulatory agencies and HTAs are increasingly
adopting real-world evidence, especially as they respond to the
COVID-19 pandemic. The
Aetion-Cegedim
Health Data partnership expansion will
grow the capacity for these bodies across Europe to use real-world
data to urgently answer questions on treatment utilization, safety,
and effectiveness.
About Aetion: Aetion is a health care analytics company that
delivers real-world evidence for the manufacturers, purchasers, and
regulators of medical treatments and technologies. The Aetion
Evidence Platform® analyzes data from the real world to produce
transparent, rapid, and scientifically validated answers on safety,
effectiveness, and value. Founded by Harvard Medical School faculty
members with decades of experience in epidemiology and health
outcomes research, Aetion informs health care’s most critical
decisions to guide product development, commercialization, and
payment innovation.
Aetion is based in New York City and backed by investors
including New Enterprise Associates (NEA), Warburg Pincus, Flare
Capital Partners, Greenspring Associates, Lakestar, B Capital,
Foresite Capital, Town Hall Ventures, McKesson Ventures, Sanofi
Ventures, EDBI, Johnson & Johnson Innovation—JJDC, Inc., UCB,
Amgen Ventures, and Horizon Health Services, Inc. Learn more at
aetion.com and follow us at @aetioninc.
About Cegedim Health Data: Cegedim Health
Data is part of the Cegedim Group, an innovative technology,
services and real world data group that has specialized in
healthcare for more than 50 years. Cegedim Health Data provides
anonymized Real-World Data and Evidence (RWD-E) platforms and
advanced studies to drive cutting-edge improvements in patient
outcomes in the interests of public health. Through THIN®️ (The
Health Improvement Network), a data history of over 25 years and
millions of anonymized patient records are immediately accessible.
Our life science users can use THIN® data across the pharma value
chain, from R&D, market access, and medical, to marketing. To
learn more, visit https://www.cegedim-health-data.com/ and follow
us on Linkedin @Cegedim Health Data and Twitter: @Cegedim_CHD.
About the Cegedim Group: Founded in 1969,
Cegedim Group is an innovative technology and services group in the
field of digital data flow management for healthcare ecosystems and
B2B, and a business software publisher for healthcare and insurance
professionals. Cegedim employs more than 5,300 people in more than
10 countries and generated revenue of nearly €500 million in 2020.
Cegedim SA is listed in Paris (EURONEXT: CGM).
To learn more, please visit:
https://www.cegedim.comAnd follow Cegedim on Twitter:
@CegedimGroup, LinkedIn and Facebook.
Aude
BalleydierCegedimMedia Relations
and Communications ManagerTel.: +33 (0)1 49 09 68
81aude.balleydier@cegedim.com |
Sandra
CarnallCegedim Health
Data UK Marketing DirectorTel : +44 (0)7702
790381sandra.carnall@cegedim.com |
Josephine TimminsNeo PR, on behalf
of Cegedim Health Data
UKAccount DirectorTel : +44 (0)1296
733867cegedim@neopr.co.uk |
|
- FINAL Aetion-Cegedim Expansion PR ENG
Cegedim (EU:CGM)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Cegedim (EU:CGM)
Historical Stock Chart
Von Apr 2023 bis Apr 2024